drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous, genetically engineered T-cell therapy expressing a single CAR with tandem scFv domains targeting CD19 or CD22 and a 4-1BB co-stimulatory domain; infused IV at 1–2×10^6 CAR-T/kg to induce T-cell cytotoxicity against malignant B cells and enhance activation, proliferation, and persistence.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a single tandem scFv CAR that recognizes CD19 or CD22 and signals via CD3zeta with a 4-1BB co-stimulatory domain. Engagement of CD19 or CD22 on malignant B cells triggers T-cell cytotoxicity and cytokine release and enhances T-cell activation, proliferation, and persistence; dual targeting helps prevent antigen-loss escape.
drug_name
CD19 & CD22 bispecific CAR T cells
nct_id_drug_ref
NCT06735495